Evaluation of Gastric Echography for Early Diagnosis of Nutritional Intolerance.
NCT ID: NCT05146908
Last Updated: 2023-10-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2021-11-29
2023-04-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Enteral nutrition is a frequent therapy in intensive care patients, and its administration is recommended. In general, nurtition is resumed early via a nasogastric tube in patients placed on mechanical ventilation. The resumption of nutrition can be seen as a "challenge" to the gastrointestinal tract, and may thus unmask underlying gastrointestinal dysfunction. Intolerance of enteral nutrition is a symptom of gastrointestinal dysfunction and is associated with poor clinical outcomes. Indeed, it is both a marker of severity by reflecting organ dysfunction and responsible for a reduction in caloric intake that can influence prognosis.
There is no consensus on the definition of intolerance to enteral nutrition. In practice, it is most often recognized because of regurgitation or vomiting, requiring reduction or discontinuation. In a recent review, the authors emphasize the need for digestive monitoring for early diagnosis of nutritional intolerance.
Gastric echography is a minimally invasive and reliable means of monitoring the gastric contents. In particular, the surface of the antrum has been validated as a way to diagnose a full stomach in intensive care. The measurement of echographic variations in gastric residue with the resumption of enteral nutrition could thus allow the early diagnosis of gastrointestinal dysfunction and food intolerance by preceding vomiting.
Our objective is to show the interest of echographic monitoring of the stomach during the resumption of enteral feeding for the diagnosis of nutritional intolerance. As nutritional intolerance is a symptom of gastrointestinal dysfunction, we will also study this phenomenon by measuring the associations between echographic data, clinical data and biomarkers of gastrointestinal dysfunction.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Early Enteral Nutrition Feeding Process Assisted by Gastrointestinal Ultrasonography
NCT05379582
Predictive Value of Transabdominal Intestine Sonography in Critically Ill Patients
NCT03589248
Non-invasive Measurement of Gastric Motility
NCT04992884
Evaluation of Gastric Insufflation Measured by Ultrasound of the Antral Surface During Optiflow Preoxygenation
NCT04206111
The Effect of Gastric Antrum Ultrasonography on Early Stage of Enteral Nutrition in Critically Ill Patients.
NCT03539653
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients in intensive care
Ventilated intubated patients for whom enteral nutrition is planned
2 Blood samples from arterial and/or central venous catheters
5 mL blood sample taken at the same time as a blood sample scheduled in regular patient management before the introduction of enteral nutrition and 24H after
Echography
In 3 steps:
* before initiation of enteral nutrition
* 4h after initiation of enteral nutrition
* After 24 hours of enteral nutrition
Data collection
At inclusion:
Calculation of severity scores; collection of reason for admission and demographic data; main comorbidities and treatments administered; the time between admission and nutritional recovery; risk factors for gastroparesis; current organ failure and supplements. Presence of parenteral nutrition, ongoing carbohydrate intake. Caloric objective.
Within the first 24 hours, collection of:
* echographic parameters at H0, H4 and H24
* venous congestion parameters
* biological parameters within 24 hours Constitution of a biobank (at H0 and H24)
Within the first 7 days, collection of:
* the occurrence or not of the primary endpoint (and time to occurrence).
* symptoms of gastrointestinal dysfunction
Within 30 days, collection of:
* organ failure and replacement over the period, and mortality.
* the occurrence or not of ventilator-associated lung disease (VAPD). Each patient is followed for 30 days. Survival will be assessed at 30 days before discharge from the study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
2 Blood samples from arterial and/or central venous catheters
5 mL blood sample taken at the same time as a blood sample scheduled in regular patient management before the introduction of enteral nutrition and 24H after
Echography
In 3 steps:
* before initiation of enteral nutrition
* 4h after initiation of enteral nutrition
* After 24 hours of enteral nutrition
Data collection
At inclusion:
Calculation of severity scores; collection of reason for admission and demographic data; main comorbidities and treatments administered; the time between admission and nutritional recovery; risk factors for gastroparesis; current organ failure and supplements. Presence of parenteral nutrition, ongoing carbohydrate intake. Caloric objective.
Within the first 24 hours, collection of:
* echographic parameters at H0, H4 and H24
* venous congestion parameters
* biological parameters within 24 hours Constitution of a biobank (at H0 and H24)
Within the first 7 days, collection of:
* the occurrence or not of the primary endpoint (and time to occurrence).
* symptoms of gastrointestinal dysfunction
Within 30 days, collection of:
* organ failure and replacement over the period, and mortality.
* the occurrence or not of ventilator-associated lung disease (VAPD). Each patient is followed for 30 days. Survival will be assessed at 30 days before discharge from the study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient admitted to intensive care
* Predicted duration of MV \> 48 hours
* Predicted start of enteral nutrition
* Time to the initiation of enteral nutrition and orotracheal intubation \< 36 hours
Exclusion Criteria
* Pregnant, parturient or breastfeeding women
* Minors
* Non echogenic patient or without an exploitable echographic window
* History of gastric or esophageal surgery
* Limitations of care
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Dijon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Dijon Bourogne
Dijon, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NGUYEN 2021-2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.